|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.02.26 - 14:03
|
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 (GlobeNewswire EN)
|
|
|
DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET....
|
|
|
|
|
|
|
09.01.26 - 13:03
|
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company′s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization (GlobeNewswire EN)
|
|
|
DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin's VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options befor...
|
|
|
|
|
09.11.25 - 22:18
|
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients (GlobeNewswire EN)
|
|
|
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular risk reduction; a pivotal moment that underscores the need for more effective, evidence-based approaches to residual CV risk....
|
|
|
|
|
|
|
|
|
|
|
|
|
14.10.25 - 14:03
|
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress (GlobeNewswire EN)
|
|
|
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease (CVD), announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress (CCC), taking place in Quebec City, Quebec, Canada from October 23 to 26, 2025. These presentations reflect the continued commitment of Amarin and HLS to advancing the broader therapeutic potential of Icosapent Ethyl (IPE) and Eicosapentaenoic Acid (EPA), further highlighting their dedication to improving cardiovascular care for appropriate patients....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
